Status:
COMPLETED
Efficacy and Safety of First-line ART With BIC/FTC/TAF Introduced at the First Clinical Visit
Lead Sponsor:
University Hospital for Infectious Diseases, Croatia
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Brief Summary
Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a recommended first-line antiretroviral regimen. Croatia has a centralized care for people living with HIV (PLWH) and all persons are s...
Eligibility Criteria
Inclusion
- HIV seropositivity confirmed by a fourth generation test
- the subject had not previously taken ART
- ART was started within 24 hours of the first examination
Exclusion
- persons under 18 years of age
- people who are pregnant, breastfeeding or planning to become pregnant
- unacceptable interaction with a drug that the subject is already taking
Key Trial Info
Start Date :
May 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2024
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT06518213
Start Date
May 1 2019
End Date
March 31 2024
Last Update
July 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital for Infectious Diseases ''Dr. Fran Mihaljevic''
Zagreb, City of Zagreb, Croatia, 10000